Skip to content

Study · Not a test of the peptide alone · 2015

2 results

Complete characterization of the mutation landscape reveals the effect on amylin stability and amyloidogenicity.

Smaoui MR, Waldispühl J

Proteins2 Apr 2015Cited by 9 (Europe PMC)

PMID25809921 (opens in a new tab)DOI10.1002/prot.24795 (opens in a new tab)PepBankPUB-25809921
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01Computer modelNot a test of Pramlintide (Symlin) aloneIn silicoOther

    In computational analyses, pramlintide was less stable than millions of predicted three-point amylin mutants.

    In plain wordsComputer models predicted lower stability for pramlintide than for millions of three-point amylin mutants.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePredicted structural stability
    Study

    n: not reported in source

    Comparator
    Predicted three-point amylin mutants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    We used the single-point mutational landscape data to generate estimations for higher-order multiple-point mutational landscapes and discovered millions of three-point mutations that are more stable and less amyloidogenic than Pramlintide.
    1 context sentence
    Summary · context
    In this work, we assist the finding of optimal analogs by computationally revealing the mutational landscape of amylin.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02Computer modelNot a test of Pramlintide (Symlin) aloneIn silicoOther

    In computational analyses, pramlintide was more amyloidogenic than millions of predicted three-point amylin mutants.

    In plain wordsComputer models predicted more amyloid formation for pramlintide than for millions of three-point amylin mutants.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreasePredicted amyloidogenicity
    Study

    n: not reported in source

    Comparator
    Predicted three-point amylin mutants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    We used the single-point mutational landscape data to generate estimations for higher-order multiple-point mutational landscapes and discovered millions of three-point mutations that are more stable and less amyloidogenic than Pramlintide.
    1 context sentence
    Summary · context
    In this work, we assist the finding of optimal analogs by computationally revealing the mutational landscape of amylin.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.